ENAapplication/xmlftp://primaryOK200GenomicsNHLBIhttps://www.ebi.ac.uk/ena/browser/view/PRJNA498560Homo sapiensBADGER is a 56-week randomized, double-blind, three-treatment, three-period cross-over trial that will evaluate the differential improvement in control that is achieved following three separate treatment interventions in children whose asthma is not acceptably controlled on a low dose of ICS (per NAEPP guidelines). All participants will enter an 8-week run-in period during which time they will receive a dose of 1x ICS (fluticasone 200 ug/day). During this 8-week time period, running 2-week averages to establish the lack of acceptable asthma control will be calculated. Thus, a child could qualify for randomization at any time during this 8-week run-in period. This approach should maximize both patient safety and successful enrollment. Children will continue to receive 1x ICS during the... (for more see dbGaP study page.)ENAfalseNHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)NHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)2025-09-242018-10-28PRJNA4985609606